HitGen Inc. A

The National Medical Products Administration will advance the implementation of the pharmaceutical trial data protection system, establish market exclusivity periods for pediatric drugs and rare disease medications, and strengthen pre-guidance for innovative drugs with new targets and mechanisms. A responsible official from the NMPA stated that it will also expand the "Spring Rain Action" for transforming clinical innovations in medical devices, and formulate clinical trial and review guiding principles in frontier areas such as brain-computer interfaces. Zhongtai Securities noted that AI4S is expanding from single-point tool applications to coordinated development across data, models, wet-lab experiments, and R&D processes, and that life science upstream and CXO companies with high-quality data accumulation, automated experimental platforms, and industrial customer bases are expected to benefit continuously. As of 11:22 on September 21, 2026, the Penghua STAR Market Healthcare ETF rose 3.87%, with constituent stock HitGen up 14.54%, and Zelgen Biopharmaceuticals and Huiyu Pharmaceutical following the gains; the Penghua Hang Seng Biotech ETF rose 4.56%.

Chengdu HitGen Pharmaceutical Development Co., Ltd. announced that its registration application for 400 million yuan of sci-tech innovation bonds has been accepted by the National Association of Financial Market Institutional Investors. The registration quota is valid for two years from the date of the notice, with Bank of Chengdu and Agricultural Bank of China as joint lead underwriters. The company may issue the bonds in tranches within the registration validity period. This matter has been reviewed and approved by the company's board of directors and extraordinary shareholders' meeting, and the issuance plan was revised in June 2026.

Chengdu HitGen released its 2026 interim report on August 26. During the reporting period, the company achieved operating revenue of 346 million yuan, up 52.41 percent year on year. Net profit attributable to the parent company was 80.68 million yuan, up 61.21 percent. Net profit after deducting non-recurring items was 76.98 million yuan, up 42.80 percent. The performance growth was mainly driven by a recovery in global demand for innovative drug research and development and strong growth across business segments. The DEL business, as the cornerstone, recorded revenue of 166 million yuan, up 62.14 percent year on year, with gross margin maintained at 77.43 percent. The OBT segment posted revenue of 54.03 million yuan, a sharp increase of 94.03 percent. The FBDD and SBDD segment led by the UK subsidiary Vernalis recorded revenue of 85.09 million yuan, up 30.43 percent. In addition, Motian Intelligence, which was consolidated as a controlling stake at the end of 2025, contributed data service revenue of 15.44 million yuan, becoming a new growth driver. The company's net cash flow from operating activities was 121 million yuan, up 9.44 percent year on year. However, affected by the appreciation of the renminbi, the company incurred exchange losses of about 14.17 million yuan during the period. Looking ahead, the company faces exchange rate fluctuation risks and goodwill impairment pressure, and needs to monitor the order conversion efficiency of the DEL and OBT segments as well as the clinical progress of proprietary pipeline projects such as HG146.

Chengdu HitGen released its 2026 half-year report. First-half net profit attributable to the parent was 80.68 million yuan, up 61.2% year on year. Operating revenue was 346 million yuan, up 52.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 76.98 million yuan, up 42.8% year on year. Net operating cash flow was 121 million yuan, up 9.4% year on year. Earnings per share were 0.2013 yuan. In the second quarter, operating revenue was 185 million yuan, up 54.2% year on year, and net profit attributable to the parent was 39.18 million yuan, up 80.1% year on year. As of the end of the second quarter, total assets were 1.995 billion yuan, up 2.1% from the end of the previous year, and net assets attributable to the parent were 1.526 billion yuan, up 1.6%. During the reporting period, all business segments achieved growth. DEL business revenue was 166 million yuan, up 62.14% year on year. FBDD and SBDD platform revenue was 85.09 million yuan, up 30.43% year on year. OBT segment revenue was 54.03 million yuan, up 94.03% year on year. TPD segment revenue was 8.46 million yuan, up 12.25% year on year.